Racial/Ethnic Disparities in Genomic Sequencing | Genetics and Genomics | JAMA Oncology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.129.82. Please contact the publisher to request reinstatement.
1.
Calvo  E, Baselga  J.  Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.  J Clin Oncol. 2006;24(14):2158-2163.PubMedGoogle ScholarCrossref
2.
Shi  Y, Au  JS-K, Thongprasert  S,  et al.  A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).  J Thorac Oncol. 2014;9(2):154-162.PubMedGoogle ScholarCrossref
3.
Lawrence  MS, Stojanov  P, Mermel  CH,  et al.  Discovery and saturation analysis of cancer genes across 21 tumour types.  Nature. 2014;505(7484):495-501.PubMedGoogle ScholarCrossref
4.
Ateeq  B, Bhatia  V, Goel  S.  Molecular discriminators of racial disparities in prostate cancer.  Trends in Cancer. 2016:2(3);116-119. doi:10.1016/j.trecan.2016.01.005.Google ScholarCrossref
5.
Spratt  DE, Osborne  JR.  Disparities in castration-resistant prostate cancer trials.  J Clin Oncol. 2015;33(10):1101-1103.PubMedGoogle ScholarCrossref
6.
Thatcher  N, Chang  A, Parikh  P,  et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).  Lancet. 2005;366(9496):1527-1537.PubMedGoogle ScholarCrossref
7.
Shaw  AT, Kim  D-W, Nakagawa  K,  et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.  N Engl J Med. 2013;368(25):2385-2394.PubMedGoogle ScholarCrossref
8.
El-Telbany  A, Ma  PC.  Cancer genes in lung cancer: racial disparities: are there any?  Genes Cancer. 2012;3(7-8):467-480.PubMedGoogle ScholarCrossref
9.
Keenan  T, Moy  B, Mroz  EA,  et al.  Comparison of the genomic landscape between primary breast cancer in African American vs white women and the association of racial differences with tumor recurrence.  J Clin Oncol. 2015;33(31):3621-3627.PubMedGoogle ScholarCrossref
10.
Yamoah  K, Johnson  MH, Choeurng  V,  et al.  Novel biomarker signature that may predict aggressive disease in African American men with prostate cancer.  J Clin Oncol. 2015;33(25):2789-2796.PubMedGoogle ScholarCrossref
Brief Report
August 2016

Racial/Ethnic Disparities in Genomic Sequencing

Author Affiliations
  • 1Department of Radiation Oncology, University of Michigan, Ann Arbor
  • 2School of Public Health, City University of New York, Hunter College, New York
  • 3Department of Biological Sciences, City University of New York, Hunter College, New York
  • 4Department of Medicine, Cornell University, Weill Cornell Medicine, New York
  • 5Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
JAMA Oncol. 2016;2(8):1070-1074. doi:10.1001/jamaoncol.2016.1854
Abstract

Importance  Although poorly understood, there is heterogeneity in the molecular biology of cancer across race and ethnicities. The representation of racial minorities in large genomic sequencing efforts is unclear, and could have an impact on health care disparities.

Objective  To determine the racial distribution among samples sequenced within The Cancer Genome Atlas (TCGA) and the deficit of samples needed to detect moderately common mutational frequencies in racial minorities.

Design, Setting, and Participants  This was a retrospective review of individual patient data from TCGA data portal accessed in July 2015. TCGA comprises samples from a wide array of institutions primarily across the United States. Samples from 10 of the 31 currently available tumor types were analyzed, comprising 5729 samples from the approximately 11 000 available.

Main Outcomes and Measures  Using the estimated median somatic mutational frequency, the samples needed beyond TCGA to detect a 10% and 5% mutational frequency over the background somatic mutation frequency were calculated for each tumor type by racial ethnicity.

Results  Of the 5729 samples, 77% (n = 4389) were white, 12% (n = 660) were black, 3% (n = 173) were Asian, 3% (n = 149) were Hispanic, and less than 0.5% combined were from patients of Native Hawaiian, Pacific Islander, Alaskan Native, or American Indian decent. This overrepresents white patients compared with the US population and underrepresents primarily Asian and Hispanic patients. With a somatic mutational frequency of 0.7 (prostate cancer) to 9.9 (lung squamous cell cancer), all tumor types from white patients contained enough samples to detect a 10% mutational frequency. This is in contrast to all other racial ethnicities, for which group-specific mutations with 10% frequency would be detectable only for black patients with breast cancer. Group-specific mutations with 5% frequency would be undetectable in any racial minority, but detectable in white patients for all cancer types except lung (adenocarcinoma and squamous cell carcinoma) and colon cancer.

Conclusions and Relevance  It is probable, but poorly understood, that ethnic diversity is related to the pathogenesis of cancer, and may have an impact on the generalizability of findings from TCGA to racial minorities. Despite the important benefits that continue to be gained from genomic sequencing, dedicated efforts are needed to avoid widening the already pervasive gap in health care disparities.

×